Cencora vs Edwards Lifesciences

Cencora (COR), health care, and Edwards Lifesciences (EW), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Cencora is worth $67.5B on the stock market and Edwards Lifesciences $61.9B: Cencora is valued at 9% more. Cencora trades at 19.7 times earnings and Edwards Lifesciences at 62.6; operating margins in their latest fiscal years were 0.82% and 20.8%. Over the past year Cencora's share price has moved -1.30% and Edwards Lifesciences's +27.5%.

Key facts

Cencora market value
$67.5B
Edwards Lifesciences market value
$61.9B
Cencora P/E
19.7
Edwards Lifesciences P/E
62.6
Cencora revenue
$321.3BFY to 2025-09-30
Edwards Lifesciences revenue
$6.1BFY to 2025-12-31
Superinvestors holding both
3

Market values as of .

Cencora vs Edwards Lifesciences: every measure side by side
Measure Cencora Edwards Lifesciences
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-09-302025-12-31
Size
Market cap$67.5Bhigher$61.9Blower
Revenue$321.3Bhigher$6.1Blower
Earnings$1.6Bhigher$1.1Blower
Employees—16,000
Total assets$76.6Bhigher$13.7Blower
Valuation
P/E19.7lower62.6higher
P/S0.2lower10.2higher
P/B18.3higher5.7lower
Dividend yield0.67%higher0.00%lower
Profitability
Operating margin0.82%lower20.8%higher
Balance sheet
Net assets$1.5Blower$10.3Bhigher
Total liabilities$74.8Bhigher$3.4Blower
Total debt$7.7Bhigher$598.3Mlower
Cash on hand$4.4Bhigher$2.9Blower
Price change
Today-0.93%lower+0.48%higher
1 year-1.30%lower+27.5%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (3)

Cencora only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Cencora / Edwards Lifesciences). Who owns COR · Who owns EW

Further comparisons

Learn

Questions and answers

Which is bigger, Cencora or Edwards Lifesciences?

By market value, Cencora is the larger: $67.5B against $61.9B for Edwards Lifesciences. By revenue in its latest fiscal year, Cencora is the larger: $321.3B against $6.1B for Edwards Lifesciences.

Which has the higher P/E ratio?

Edwards Lifesciences: 62.6, against 19.7 for Cencora. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Edwards Lifesciences: 20.8%, against 0.82% for Cencora. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Cencora: 0.67%, against 0.00% for Edwards Lifesciences. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Cencora: $7.7B, against $598.3M for Edwards Lifesciences. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Cencora and Edwards Lifesciences?

In their latest 13F filings, Steve Cohen, Ken Griffin and Israel Englander hold both.

Cite this page

Funkfolio, “Cencora vs Edwards Lifesciences”, data as of 17 November 2026. https://funkfolio.com/compare/cor-vs-ew

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.